MapLight Therapeutics, Inc.·4

Feb 24, 6:57 PM ET

Malenka Robert C. 4

4 · MapLight Therapeutics, Inc. · Filed Feb 24, 2026

Insider Transaction Report

Form 4
Period: 2026-02-20
Transactions
  • Sale

    Voting Common Stock

    [F1][F2]
    2026-02-20$18.03/sh2,195$39,576337,059 total
  • Sale

    Voting Common Stock

    [F1][F3]
    2026-02-23$18.39/sh10,788$198,391326,271 total
  • Sale

    Voting Common Stock

    [F1][F4]
    2026-02-23$19.06/sh476$9,073325,795 total
  • Sale

    Voting Common Stock

    [F1][F5]
    2026-02-24$18.15/sh736$13,358325,059 total
Holdings
  • Voting Common Stock

    [F6]
    (indirect: See footnote)
    31,672
Footnotes (6)
  • [F1]Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.
  • [F2]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F5]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.01 to $18.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F6]The shares are held by the Robert C. Malenka Living Trust U/A DTD 08/21/2012, of which the Reporting Person is the sole trustee and has voting and dispositive power.
Signature
/s/ Kristopher L. Hanson, Attorney-in-Fact|2026-02-24

Documents

1 file
  • 4
    form4-02242026_110209.xmlPrimary